argenx BVBA (ARGX) - Long-Term Debt to Capital Coefficient
argenx SE (ARGX) integrates ESG principles into its biomedical research, focusing on ethics and ecology. The operating model relies on the full outsourcing of production and trials, which minimizes capital expenditures. The confirmed price history on the GURU.Markets platform chart, where the indicator is 0.00, complements the development of the rare disease treatment ecosystem through the expansion of indications for the drug Vyvgart.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_ARGX_-_argenx-SE_-_Long-Term-Debt-to-Capital "ARGX: argenx Long-Term Debt to Capital 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for argenx SE (ARGX)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
General company analysis:argenx N.V. - ARGX
For an investor, the long-term reliability of an issuer is determined by the balance between debt and equity, where this ratio measures the proportion of loans with a maturity of over one year within the capital structure. By analyzing the level of long-term debt-to-equity, one can assess the impact of WACC on business valuation, which in the case of argenx SE (ARGX) confirms the financial stability of Tim Van Hauweriken's team during global sales expansion.
Key competitors
BioNTech Inc. - Long-Term Liabilities to Equity|Long-Term Debt to Capital ABVX|ADMA (ADMA Corp) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PTGX (Protagonist Therapeutics)|Long-Term Debt to Capital immunovant.com IMVT|KNSA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital biocryst.com|Long-Term Debt to Equity Ratio VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PHVS (Pharvaris Corp)|Ratio of Long-Term Indebtedness to Capital AbCellera (ABCL)|TRML - Long-Term Debt to Equity|precigen.com (PGEN) - Long-Term Debt to Equity Ratio|Pharming Group (PHAR) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Nektar Therapeutics Inc|Long-Term Debt to Equity Ratio UPB|Long-Term Debt to Capital Zenas Corp|Long-Term Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Long-Term Liabilities to Capital|Pieris Pharmaceuticals Inc - Long-Term Debt to Capital|SVRA - Long-Term Debt to Capital|Rigel Pharmaceuticals (RIGL) - Long-Term Debt to Equity|anaptysbio.com - Long-Term Debt to Capital Coefficient|ATXS (Astria Therapeutics, Inc.) - Long-Term Debt to Capital|ENGN - Long-Term Indebtedness to Equity|Long-Term Debt to Capital RAPT|JBIO - Long-Term Liabilities to Capital|Long-Term Debt to Equity Aclaris Therapeutics ACRS|KYTX: Long-Term Debt to Capital Ratio|TLSA: Long-Term Debt to Equity Ratio|CABA (Cabaletta Bio Inc.) - Long-Term Debt to Capital Ratio|VTYX (Ventyx Bio) - Long-Term Debt to Equity Ratio|Theratechnologies, Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Avalo Therapeutics, Inc|eledon.com (ELDN) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital AGEN|CLYM - Long-Term Liabilities to Capital|Long-Term Debt to Capital ZURA (Zura Bio Limited)|Long-Term Debt to Capital aTyr Pharmaceuticals ATYR|ADAG - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient IMA (ImageneBio Inc)|STTK: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Equillium EQ|Long-Term Debt to Equity Ratio CNTB|Long-Term Debt to Capital Ratio IMUX (Immunic Inc)|Long-Term Debt to Equity Atara Biotherapeutics (ATRA)|IFRX: Long-Term Liabilities to Equity|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|Long-Term Debt to Capital Coefficient ACET|Celularity Corp - Long-Term Debt to Capital|INMB - Long-Term Debt to Capital|Barinthus Biotherapeutics (BRNS) - Long-Term Debt to Equity|kezarlifesciences.com - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity SAB Biotherapeutics, Inc.|Long-Term Debt to Equity Ratio Akari Therapeutics PLC (AKTX)|Long-Term Debt to Capital ENLV|Long-Term Debt to Capital q32bio.com (QTTB)|GeoVax Labs, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient EDSA|iBio - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Carisma Therapeutics CARM|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Bolt Biotherapeutics, Inc.|Long-Term Debt to Equity HCW Biologics, Inc.|Long-Term Debt to Equity Ratio Aptevo (APVO)|Long-Term Debt to Equity Ratio AIM (AIM ImmunoTech)|Long-Term Debt to Capital aditxt.com (ADTX)|Long-Term Debt to Equity GRI Bio Corp GRI|XRTX: Long-Term Debt to Capital Ratio|Vyome Holdings Inc - Long-Term Debt to Capital|Long-Term Liabilities to Capital revbiosciences.com|INDP: Long-Term Debt to Capital|Scinai Immunotherapeutics Ltd (SCNI) - Long-Term Debt to Capital|Long-Term Debt to Equity CalciMedica Inc|AFMD: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ALLK|hookipapharma.com (HOOK) - Long-Term Indebtedness to Equity|Long-Term Debt to Capital IGMS (IGM Biosciences)|iTeos Therapeutics Inc (ITOS) - Long-Term Liabilities to Capital|OCEA - Long-Term Debt to Equity|TCBP (TC BioPharm Ltd) - Long-Term Debt to Capital Ratio|THRD (Third Harmonic Bio) - Long-Term Debt to Equity Ratio